Hi folks
Everything about these results scream Buy.
But the only thing wrong about this company is its lack of market penetration and its lack of revenue resulting in cash burn.
Great science, below par management and marketing.
Just my opinion , as always DYOR.
cheer Lies
Ann: Leading Microbiology Journal Publishes APAS Clinical Data, page-6
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
0.001(3.33%) |
Mkt cap ! $25.08M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.6¢ | 1.5¢ | $3.118K | 204.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 2602938 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 1568400 | 5 |
View Market Depth
| Last trade - 13.24pm 23/08/2024 (20 minute delay) ? |
| LBT (ASX) Chart |